P504S expressing circulating prostate cells as a marker for prostate cancer

Oncology Reports

Volumn 24, Issue 3, 2010, Pages 687-692

  Murray, Nigel P ^a,b,c   Calaf, Gloria M ^d,e   Badinez, Leonardo ^f,g   Dueña, Ricardo ^a   Badinez, Orlando ^g   Orellana, Nelson ^a   Reyes, Eduardo ^h   Fuentealba, Cinthia ^h  

^a Department of Oral and Maxillofacial Surgery   (Chile)

^b Instituto de Bio Oncología   (Chile)

^c UNIVERSIDAD MAYOR   (Chile)

^d UNIVERSIDAD DE TARAPACÁ   (Chile)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f Centro Oncológico Fundación Arturo López Pérez   (Chile)

^g Instituto Radio Oncológico Santiago   (Chile)

^h UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

Author keywords

Cancer detection; Disseminated tumor cells; Matrix metalloproteinase 2; P504S; Prostate cancer; Prostate specific antigen

Indexed keywords

CD82 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GRADING; CANCER SCREENING; CENTRIFUGATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION;

AGE FACTORS; AGED; ANTIGENS, CD82; BIOPSY; CELL SEPARATION; CHI-SQUARE DISTRIBUTION; CHILE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 77956336142     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000908     Document Type: Article

References (28)

1. Szot J: Epidemiological analysis of mortality caused by solid tumors in the Metropolitan Region, Chile, 1999. Rev Med Chile 131: 641-649, 2003.
2. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA and Kuntz KM: Impact of age, benign prostatic hyperplasia and cancer on prostate specific antigen levels. Cancer 106: 1507-1513, 2006.
3. Bozeman CB, Carver BS, Eastham JA and Venable DD: Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol 167: 1723-1726, 2002. (Pubitemid 34240711)
4. Catalona WJ, Smith DS, Ratliff TL and Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270: 948-954, 1993.
5. Gann PH, Hennekens CH and Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273: 289-294, 1995.
6. Krumholtz JS, Carvalhal GF, Ramos CG, et al: Prostate-specific antigen cut-off of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features. Urology 60: 469-474, 2002.
7. Catalona WJ, Smith DS and Ornstein DK: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277: 1452-1455, 1997.
8. Horninger W, Berger AP, Rogatsch H, et al: Characteristics of prostate cancers detected at low PSA level. Prostate 58: 232-237, 2004.
9. Thompson IM, Pauler DK, Goodman PJ, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per millimeter. N Eng J Med 350: 2239-2246, 2004.
10. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH and Carter HB: Low level of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study on Aging. Urology 58: 411-416, 2001. (Pubitemid 32816360)
11. Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK and Nadler RB: Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67: 316-320, 2006.
12. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland SG and Gomella LG: Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 52: 6110-6112, 1992.
13. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG and Terstappen LW: Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65: 713-718, 2005. (Pubitemid 40523005)
14. Chen BT, Loberg A, Neeley CK, et al: Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology 65: 616-621, 2005.
15. Wang ZP, Eisenberger MA, Carducci MA, Partin AW, Scher HI and Tsò PO: Identification and characterization of circulating prostate carcinoma cells. Cancer 88: 2787-2795, 2000.
16. Murray NP: El uso de doble-inmumomarcación para detectar células prostáticas en la circulación sanguínea en pacientes con cáncer prostática y las correlaciones con los parámetros clínicos. Rev Chil Urol 71: 135-140, 2006.
17. Jiang Z, Fanger GR, Wodo BA, et al: Expression of alpha-methylacyl-CoA racemase (P504S) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol 34: 792-796, 2003.
18. Murray NP and Badinez L: Las células prostáticas en al circulación sanguínea en pacientes con cáncer prostático expresan la proteína P504S: un estudio utilizando inmunocitoquímica. Rev Chil Urol 73: 54-57, 2008.
19. Bouras T and Frauman AG: Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: a biphasic relationship with tumour grade. J Pathol 188: 382-388, 1999. (Pubitemid 29327436)
20. Murray NP: La expresión de HER-2 en células prostáticas en la circulación sanguínea y el efecto de la supresión androgénica en hombres con cáncer prostático. Rev Chil Urol 72: 190-194, 2007.
21. Murray NP and Badinez L: Expression of HER-2 in disseminated tumor cells in bone marrow of patients with prostate cancer is associated with resistance to androgen blockage but not DES. Urology 72 (Suppl. 5A): S65, 2008.
22. Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA Jr and Kallakury BV: Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 16: 198-205, 2003.
23. Borgen E, Naume B, Nesland JM, et al: Standardization of the immunocytochemical detection of cancer cells in BM and blood: establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 5: 377-388, 1999.
24. Osman I, Scher HI, Drobnjak M, et al: HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 7: 2643-2647, 2001.
25. Trudel D, Fradet Y, Meyer F, Harel F and Têtu B: Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res 63: 8511-8515, 2003.
26. British Cancer Registry: Health Ministry United Kingdom, Department of Statistics, London, 2007.
27. Reissigl A, Horninger W, Fink K, Klocker H and Barjch G: Prostate carcinoma screening in the county of Tyrol, Austria: experience and results. Cancer 80: 818-829, 1997.
28. Babaian RJ, Johnson DA, Naccarato W, Ayala A, Bhadkamker VA and Fritsche HA Jr: The incidence of prostate cancer in a screening population with a serum PSA between 2.5 and 4.0 ng/ml. J Urol 165: 757-760, 2001.